Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate OLE in Primary Generalized Tonic-Clonic Seizures
NCT03961568Phase 3Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Aug 2019
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of cenobamate in primary generalized tonic-clonic seizure (PGTCS), sponsored by SK Life Science, Inc.. Started Aug 2019; status: completed.
02
Drugs
cenobamate
03
Conditions
primary generalized tonic-clonic seizure (PGTCS)
Beyond the preview
Go deeper on NCT03961568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961568.